Eli Lilly and Company, one of the three main insulin manufacturers in the United States, made headlines last week after a Twitter user took advantage of Elon Musk’s bungling management of the microblogging platform to claim insulin was now free — causing Eli Lilly’s stock to drop about four percent and triggering a social media firestorm over the high price of insulin. In retaliation, Eli Lilly halted all advertising on Twitter, delivering another blow to the platform that is already coping with an advertiser exodus.

In truth, Eli Lilly will be fine. However, there’s one important, struggling insulin-related company that didn’t get as much attention last week — but whose troubles might have much wider implications for diabetes patients living in the United States. Insulin pump manufacturer Tandem Diabetes Care saw its stock plummet more than 20 percent this month — five times the drop suffered by Eli Lilly — after a dismal quarterly earnings report. Overall, the company’s stock is down 66 percent this year.

What makes this development so interesting is that the company’s executives are expressly blaming its poor sales on the lack of universal health care in this country.